Immunogenetics of some connective tissue disorders

Document Type : Original Article


1 Department of Clinical Pathology,Faculty of Medicine, Sohag University.

2 Department of Clinical and Pathology,sohag faculty of medicine,sohag university

3 Department of Clinical and Chemical pathology, Sohag Faculty of Medicine, Sohag University.


 Connective tissue diseases (CTDs) are systemic autoimmune disorders characterized by a large spectrum of clinical features and multisystemic involvement. Connective tissue disease is any disease that has the connective tissues of the body as a target of pathology.
Connective tissue is any type of biological tissue with an extensive extracellular matrix that supports, binds together, and protects organs. These tissues form a framework, or matrix, for the body, and are composed of two major structural protein molecules: collagen and elastin.
 Autoimmunity involves the loss of normal immune homeostasis such that the organism produces an abnormal response to its own self tissue. The hallmark of autoimmune diseases generally involves the presence of self-reactive T cells, autoantibodies and inflammation

2871- Iaccarino L, Ghirardello A, CanovaM, ZenM, Bettio S and Nalotto L. (2011): Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. 10:553–8.
2- PanneerDevaraju, ReenaGulati, Paul T, Antony CB and Mithun. (2015): Susceptibility to SLE in South Indian Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 genes. Volume 64, Issue 1, March 2015, Pages 123–126
3- Somers EC, Marder W and Cagnoli P. (2014): Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol (Hoboken NJ) 66(2):369–378
5- Tsokos GC. (2011): "Systemic lupus erythematosus". N. Engl. J. Med. 365 (22): 2110–21
4-  Murphy, G; Isenberg, D (2013): "Effect of gender on clinical presentation in systemic lupus erythematosus.". Rheumatology (Oxford, England) 52 (12): 2108–15
6- Borgia RE and Silverman ED (2015): "Childhood-onset systemic lupus erythematosus: an update.". Current opinion in rheumatology 27 (5): 483–9
7- Bertsias GK, Salmon JE and Boumpas DT. (2010): Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis. 69:1603-1611
8- Jeleniewicz R, Suszek D and Majdan M. (2015): Clinical picture of late-onset systemic lupus erythematosus in a group of Polish patients, Pol Arch Med Wewn. 125(7-8):538-44. Epub 2015 Jun 15
9-George Bertsias, RicardCervera and Dimitrios T Boumpas, (2012): EULAR Textbook on Rheumatic Diseases, Systemic Lupus Erythematosus: Pathogenesis and Clinical Feature. ch 20,479-505
10- Javierre BM, Fernandez AF and Richter J. (2010): Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 20:170-179
11- Somers EC and Richardson BC. (2014): Environmental exposures, epigenetic changes and the risk of lupus. Lupus. 23(6):568–76.
12- Rasmussen NS, Draborg AH, Nielsen CT, Jacobsen S and Houen G. (2015): Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand J Rheumatol. 44(2):143–9
13- Mak A, Tay S (2014): Environmental factors, toxicants and systemic lupus erythematosus. Int J MolSci 15(9):16043–16056.
14- Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R and Shi H. (2014): Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 40(1):128–39.
15- Kassi E and Moutsatsou P. (2010): Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2010: 317452..
16- Agarwal SK. (2011): Core management principles in rheumatoid arthritis to help guide managed care professionals. Nov-Dec;17(9 Suppl B): S03-8.
17- Scott DL, Wolfe F and Huizinga TW. (2010): "Rheumatoid arthritis". Lancet 376 (9746): 1094–108.
18- Svendsen AJ, Junker P, Houen G, Kyvik KO, Nielsen C, Skytthe A, Holst R. (2016): Incidence of chronic persistent rheumatoid arthritis and the impact of smoking. Arthritis Care Res (Hoboken). Jul 7
19- MacGregor AJ, Snieder H and Rigby AS. (2010): Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43:30-7.
20-  Gregersen PK, Silver J and Winchester RJ. (2011): The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30:1205- 13
21- De Almeida DE, Ling S, Pi X, Hartmann-Scruggs AM, Pumpens P and Holoshitz J. (2010): Immune dysregulation by the rheumatoid arthritis shared epitope. J Immunol. 185:1927-34..
22- Klareskog L, Ronnelid J, Lundberg K, Padyukov L and Alfredsson L. (2008): Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 26:651-75.
23- De Rycke L, Peene I and Hoffman IE. (2011): Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular manifestations. Ann Rheum Dis. 63:1587-93.
24- Mahdi H, Fisher BA and Kallberg H. (2009): Specific interaction between genotype, smoking and autoimmunity to citrullinated- alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet. 41:1319- 24
25- Wegner N, Wait R and Sroka A. (2010): Peptidylargininedeiminase from Porphyromonasgingivaliscitrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 62:2662-72..
26- Scher JU, Ubeda C, Pillinger MH, et al. (2010): Characteristic oral and intestinal microbiota in rheumatoid arthritis (RA): a trigger for autoimmunity? Arthritis Rheum. 62:Suppl:1390.
27-Wu M, Schneider DJ, Mayes MD, Assassi S, Arnett FC, Tan FK, Blackburn MR and Agarwal SK. (2012): The role of type 1 interferon in systemic sclerosis. Jun;132(6):1605-14.
28- Vikram B.(2013): A rare case of hidebound disease with dental implications. Dent Res J (Isfahan). 10(4):556–61.
29- Careta MF and Romiti R. (2015): Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 90(1):62–73.
30- Michael. (2012): Sticherling Systemic sclerosis – dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings. Volume 10, Issue 10 October. Pages 705–716
31- Tyndall A and Fistarol S. (2013): The differential diagnosis of systemic sclerosis. CurrOpinRheumatol. 25:692–9.
32- Nguyen C, Berezne A, Baubet T, et al. (2011): Association of Gender with Clinical Expression, Quality of Life, Disability, and Depression and Anxiety in Patients with Systemic Sclerosis. PLoS One. Mar 9. 6(3): e17551.
33- Ungprasert P, Srivali N and Kittanamongkolchai W. (2015): Systemic sclerosis and risk of venous thromboembolism: A systematic review and meta-analysis. Mod Rheumatol. Apr 7. 1-17
34- Arora-Singh RK. (2010): Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. J. Autoimmun. 35, 52–57.
35- Broen JC, Coenen M J, and Radstake T R. (2012): Genetics of systemic sclerosis: an update. Curr. Rheumatol. Rep. 14, 11–21.
36- Gorlova O. (2011): Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet. 7, e1002178.
37- Mayes MD. (2014): Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am. J. Hum. Genet. 94, 47–61
38- Ballestar E. (2011): Epigenetic alterations in autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 7, 263–271.
39- Marie I. (2014): Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun. Rev. 13, 151–156.
40-Mammen AL. (2010): Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Jan;1184:134-53.
 41- Bendewald MJ, Wetter DA, Li X and Davis MD. (2010): Incidence of dermatomyositis and clinically amyopathicdermatomyositis: apopulation-based study in Olmsted County, Minnesota. Arch Dermatol. Jan. 146(1):26-30.
42- PauliusVenalis and Ingrid E. (2014): Lundberg. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology Journal. 53:397_405.
43- Betteridge ZE, Gunawardena H and McHugh NJ. (2011): Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 13:209.
44- Delaleu N, Nguyen CQ, Peck AB and Jonsson R. (2011): Sjögren's syndrome: studying the disease in mice. Jun 13;13(3):217.
45- Helmick CG, Felson DT and Lawrence RC. (2008): Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. Jan. 58(1):15-25.
46- Sisto M. (2011): A failure of TNFAIP3 negative regulation maintains sustained NF-κB activation in Sjögren‘s syndrome. Histochem. Cell Biol. 135, 615–625.
47- Lessard CJ. (2013): Identification of multiple Sjögren’s syndrome susceptibility loci [abstract OP0020]. Ann. Rheum. Dis. 72 (Suppl. 3), 54.